IHC ER PR HER2 NEU KI67 Breast Cancer Biomarker Panel
Comprehensive Breast Cancer Biomarker Analysis
The IHC ER PR HER2 NEU KI67 Breast Cancer Biomarker Panel represents a cutting-edge diagnostic approach in breast cancer management. This comprehensive immunohistochemistry test provides critical information about tumor characteristics that directly influence treatment decisions and prognosis assessment. By analyzing five essential biomarkers simultaneously, healthcare providers can develop personalized treatment strategies tailored to each patient’s specific cancer subtype.
What This Advanced Test Measures
This sophisticated panel evaluates multiple biomarkers that define breast cancer behavior and treatment responsiveness:
- Estrogen Receptors (ER): Determines if cancer cells have estrogen receptors, indicating potential responsiveness to hormone therapy
- Progesterone Receptors (PR): Assesses progesterone receptor status for additional hormone therapy guidance
- HER2/neu Protein: Identifies HER2-positive cancers that may benefit from targeted therapies like Herceptin
- KI67 Proliferation Index: Measures the percentage of actively dividing cancer cells, indicating tumor aggressiveness
Who Should Consider This Comprehensive Biomarker Testing
This advanced diagnostic panel is essential for individuals with:
- Newly diagnosed breast cancer requiring comprehensive biomarker profiling
- Recurrent breast cancer needing updated biomarker assessment
- Metastatic breast cancer where treatment planning depends on biomarker status
- Patients considering targeted therapy or hormone treatment options
- Those requiring prognostic information for treatment decision-making
Clinical Indications and Symptoms
Patients presenting with breast abnormalities, suspicious mammogram findings, or confirmed breast cancer diagnosis should discuss this comprehensive biomarker testing with their healthcare provider. The test is particularly valuable when:
- Planning systemic therapy for invasive breast cancer
- Determining eligibility for specific targeted treatments
- Assessing cancer aggressiveness and growth potential
- Developing long-term management strategies
Significant Benefits of Comprehensive Biomarker Analysis
Undergoing the IHC ER PR HER2 NEU KI67 panel provides numerous advantages for breast cancer management:
- Personalized Treatment Planning: Enables selection of therapies specifically targeting your cancer’s molecular characteristics
- Prognostic Information: Provides insights into cancer behavior and potential treatment response
- Therapy Optimization: Helps avoid ineffective treatments and minimize unnecessary side effects
- Comprehensive Assessment: Multiple biomarkers analyzed simultaneously for complete picture
- Evidence-Based Decisions: Supports treatment choices with solid scientific data
Understanding Your Test Results
Your comprehensive biomarker results will provide detailed information about each tested component:
- ER/PR Status: Positive results indicate hormone receptor-positive cancer, typically responsive to hormone therapy
- HER2 Status: Positive findings suggest eligibility for HER2-targeted therapies
- KI67 Index: Higher percentages indicate more aggressive, rapidly dividing cancer cells
- Combined Interpretation: Your oncologist will integrate all results to determine your specific breast cancer subtype
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | IHC ER PR HER2 NEU KI67 Breast Cancer Biomarker Panel |
| Discount Price | $226 USD |
| Regular Price | $300 USD |
| Turnaround Time | 6 Days |
| Sample Type | Tissue in 10% Neutral Buffered Formalin |
| Method | Histopathology |
Important Pre-Test Information
This comprehensive biomarker testing requires a doctor’s prescription for proper medical supervision. Prescription requirements do not apply to surgical cases, pregnancy-related testing, or individuals planning international travel. Our experienced team ensures proper sample handling and accurate interpretation of results.
Nationwide Accessibility
We maintain diagnostic facilities across major metropolitan areas throughout the United States, including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network ensures convenient access to advanced breast cancer biomarker testing regardless of your location.
Take Control of Your Breast Cancer Journey
Understanding your breast cancer’s molecular characteristics is the first step toward effective, personalized treatment. Our comprehensive IHC ER PR HER2 NEU KI67 panel provides the critical information needed to make informed decisions about your care pathway.
Ready to schedule your comprehensive breast cancer biomarker testing? Contact our dedicated team today at +1(267) 388-9828 or book your appointment online. Our genetic specialists are available to discuss testing options and answer any questions about the IHC ER PR HER2 NEU KI67 panel and its role in your breast cancer management strategy.
